Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) saw strong trading volume on Thursday . 1,826,495 shares traded hands during trading, an increase of 417% from the previous session’s volume of 353,165 shares.The stock last traded at $0.28 and had previously closed at $0.23.

Several equities research analysts recently commented on the company. ValuEngine cut ContraVir Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Maxim Group cut ContraVir Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th.

A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Barclays PLC raised its holdings in shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 229.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 179,480 shares of the biopharmaceutical company’s stock after buying an additional 124,958 shares during the quarter. Barclays PLC owned about 1.08% of ContraVir Pharmaceuticals worth $50,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 4.48% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/contravir-pharmaceuticals-ctrv-sees-large-volume-increase/2955916.html.

About ContraVir Pharmaceuticals (NASDAQ:CTRV)

ContraVir Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection.

See Also: S&P 500 Index

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.